Treatment of calcium channel blocker-induced cardiovascular toxicity with drug scavenging liposomes

Biomaterials

Volumn 33, Issue 13, 2012, Pages 3578-3585

  Forster, Vincent ^a   Luciani, Paola ^a   Leroux, Jean Christophe ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Blood pressure; Calcium channel blocker; Drug uptake; Intoxication; Liposome

Indexed keywords

ACUTE TOXICITY; BI-LAYER STRUCTURE; CALCIUM CHANNEL BLOCKER; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; DETOXIFYING AGENTS; DILTIAZEM; DRUG UPTAKE; DUAL EFFECT; IN-SITU; IN-VITRO; INTERNAL PH; INTOXICATION; INTRAVENOUS INJECTIONS; LONG-CIRCULATING LIPOSOMES; MEAN PRESSURES; NANOCARRIERS; PHARMACOLOGICAL EFFECTS; PROTECTIVE EFFECTS; TRANSMEMBRANES; VASCULAR TISSUE; VERAPAMIL;

ANIMALS; BLOOD PRESSURE; CALCIUM; HISTOLOGY; LIPID BILAYERS; LIPOSOMES; TISSUE; TOXICITY;

PHOSPHOLIPIDS;

ANTIDOTE; DILTIAZEM; LIPOSOME; LONG CIRCULATING PH GRADIENT LIPOSOME; UNCLASSIFIED DRUG; VERAPAMIL;

AREA UNDER THE CURVE; ARTICLE; CARDIOTOXICITY; DIASTOLIC BLOOD PRESSURE; DRUG DETOXIFICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INHIBITION; DRUG INTOXICATION; DRUG STABILITY; HEART HEMODYNAMICS; LIPID BILAYER; MEAN ARTERIAL PRESSURE; MEMBRANE STRUCTURE; PH; PRIORITY JOURNAL; SURFACE CHARGE; SYSTOLIC BLOOD PRESSURE; TELEMETRY;

ANIMALS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR SYSTEM; DILTIAZEM; DRUG CARRIERS; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRAVENOUS; KINETICS; LIPOSOMES; MALE; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; VERAPAMIL;

ANIMALIA; RATTUS;

EID: 84857445278     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.01.042     Document Type: Article

References (38)

1. Bronstein A.C., Spyker D.A., Cantilena L.R., Green J.L., Rumack B.H., Giffin S.L. 2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report. Clin Toxicol 2010, 48:979-1178.
2. Henry P.D. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol 1980, 46:1047-1058.
3. American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists Position paper: single-dose activated charcoal. Clin Toxicol 2005, 43:61-87.
4. Buckley N., Dawson A.H., Howarth D., Whyte I.M. Slow-release verapamil poisoning. Use of polyethylene glycol whole-bowel lavage and high-dose calcium. Med J Aust 1993, 158:202-204.
5. Cumpston K.L., Aks S.E., Sigg T., Pallasch E. Whole bowel irrigation and the hemodynamically unstable calcium channel blocker overdose: primum non nocere. J Emerg Med 2010, 38:171-174.
6. Leroux J.-C. Injectable nanocarriers for biodetoxification. Nat Nanotechnol 2007, 2:679-684.
7. Cave G., Harvey M. Intravenous lipid emulsion as antidote beyond local anesthetic toxicity: a systematic review. Acad Emerg Med 2009, 16:815-824.
8. Jamaty C., Bailey B., Larocque A., Notebaert E., Sanogo K., Chauny J.-M. Lipid emulsions in the treatment of acute poisoning: a systematic review of human and animal studies. Clin Toxicol 2010, 48:1-27.
9. ® therapy during treatment of an overdose. Clin Toxicol 2011, 49:340-344.
10. Niiya T., Litonius E., Petäjä L., Neuvonen P.J., Rosenberg P.H. Intravenous lipid emulsion sequesters amiodarone in plasma and eliminates its hypotensive action in pigs. Ann Emerg Med 2010, 56:402-408.
11. Marwick P.C., Levin A.I., Coetzee A.R. Recurrence of cardiotoxicity after lipid rescue from bupivacaine-induced cardiac arrest. Anesth Analg 2009, 108:1344-1346.
12. Harvey M., Cave G., Kazemi A. Intralipid infusion diminishes return of spontaneous circulation after hypoxic cardiac arrest in rabbits. Anesth Analg 2009, 108:1163-1168.
13. Mirtallo J.M., Dasta J.F., Kleinschmidt K.C., Varon J. State of the art review: intravenous fat emulsions: current applications, safety profile, and clinical implications. Ann Pharmacother 2010, 44:688-700.
14. Dhanikula A.B., Lamontagne D., Leroux J.-C. Rescue of amitriptyline-intoxicated hearts with nanosized vesicles. Cardiovasc Res 2007, 74:480-486.
15. Bertrand N., Bouvet C., Moreau P., Leroux J.-C. Transmembrane pH-gradient liposomes to treat cardiovascular drug intoxication. ACS Nano 2010, 4:7552-7558.
16. Hope M., Bally M., Webb G., Cullis P.R. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta 1985, 812:55-65.
17. Luciani P., Fevre M., Leroux J.-C. Development and physico-chemical characterization of a liposomal formulation of istaroxime. Eur J Pharm Biopharm 2011, 79:285-293.
18. Adeyemi O., Roberts S., Harris J., West H., Shome S., Dewhurst M. QA interval as an indirect measure of cardiac contractility in the conscious telemeterised rat: model optimisation and evaluation. J Pharmacol Toxicol Methods 2009, 60:159-166.
19. Ramoska E.A., Spiller H.A., Winter M., Borys D. A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment. Ann Emerg Med 1993, 22:196-200.
20. Madden T.D., Harrigan P.R., Tai L.C.L., Bally M.B., Mayer L.D., Redelmeier T.E., et al. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient - a survey. Chem Phys Lipids 1990, 53:37-46.
21. Cullis P.R., Hope M.J., Bally M.B., Madden T.D., Mayer L.D., Fenske D.B. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta-Biomembr 1997, 1331:187-211.
22. Demel R., De Kruyff B. The function of sterols in membranes. Biochim Biophys Acta 1976, 457:109-132.
23. Kirby C., Clarke J., Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J 1980, 186:591-598.
24. Webb M.S., Harasym T.O., Masin D., Bally M.B., Mayer L.D. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 1995, 72:896-904.
25. Hwang K.J., Luk K.F., Beaumier P.L. Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study. Proc Natl Acad Sci U S A 1980, 77:4030-4034.
26. Leaver J., Alonso A., Durrani A.A., Chapman D. The physical properties and photopolymerization of diacetylene-containing phospholipid liposomes. Biochim Biophys Acta-Biomembr 1983, 732:210-218.
27. Huang Z., Szoka F.C. Sterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane properties. J Am Chem Soc 2008, 130:15702-15712.
28. Smith H.J., Goldstein R.A., Griffith J.M., Kent K.M., Epstein S.E. Regional contractility. Selective depression of ischemic myocardium by verapamil. Circulation 1976, 54:629-635.
29. Nayler W.G., Szeto J. Effect of verapamil on contractility, oxygen utilization, and calcium exchangeability in mammalian heart muscle. Cardiovasc Res 1972, 6:120-128.
30. Oney S., Lam R.T.S., Bompiani K.M., Blake C.M., Quick G., Heidel J.D., et al. Development of universal antidotes to control aptamer activity. Nat Med 2009, 15:1224-1228.
31. Webb M.S., Wheeler J.J., Bally M.B., Mayer L.D. The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery. Biochim Biophys Acta-Biomembr 1995, 1238:147-155.
32. Li X., Hirsh D.J., Cabral-Lilly D., Zirkel A., Gruner S.M., Janoff A.S., et al. Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim Biophys Acta-Biomembr 1998, 1415:23-40.
33. Surakitbanharn Y., McCandless R., Krzyzaniak J.F., Dannenfelser R.-M., Yalkowsky S.H. Self-association of dexverapamil in aqueous solution. J Pharm Sci 1995, 84:720-723.
34. Mayer L.D., Reamer J., Bally M.B. Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation. J Pharm Sci 1999, 88:96-102.
35. Pütz G., Schmah O., Eckes J., Hug M.J., Winkler K. Controlled application and removal of liposomal therapeutics: Effective elimination of pegylated liposomal doxorubicin by double-filtration plasmapheresis in vitro. J Clin Apher 2010, 25:54-62.
36. Mannock D.A., McIntosh T.J., Jiang X., Covey D.F., McElhaney R.N. Effects of natural and enantiomeric cholesterol on the thermotropic phase behavior and structure of egg sphingomyelin bilayer membranes. Biophys J 2003, 84:1038-1046.
37. Mantsch H.H., Hsi S.C., Butler K.W., Cameron D.G. Studies on the thermotropic behavior of aqueous phosphatidylethanolamines. Biochim Biophys Acta-Biomembr 1983, 728:325-330.
38. Riske K.A., Döbereiner H.-G., Lamy-Freund M.T. Gel-fluid transition in dilute versus concentrated DMPG aqueous dispersions. J Phys Chem B 2002, 106:239-246.